Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.86 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.86 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14981676 | 0.93 | PARP1 (1.00) | PARP1PARP2HTR1AHTR7CHRNA7 | |
| SCHEMBL6796319 | 0.87 | PARP1 (0.81) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL6795915 | 0.80 | PARP1 (0.70) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL31060680 | 0.80 | PARP1 (1.00) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL3400063 | 0.79 | PARP1 (0.75) | PARP1PARP2 | |
| SCHEMBL6800854 | 0.79 | PARP1 (1.00) | PARP1PARP2HTR1AHTR7CHRNA7 | |
| SCHEMBL9009912 | 0.78 | PARP1 (0.67) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL6791769 | 0.78 | PARP1 (1.00) | PARP1 | |
| SCHEMBL9009907 | 0.77 | PARP1 (0.67) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL14129617 | 0.77 | PARP1 (0.64) | PARP1PARP2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | PARP1 1/4885PARP2 3/4885HTR1A 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.